Literature DB >> 26327709

Histiocytoid Variant of Sweet Syndrome Associated with Azacitidine and Recurrence upon Rechallenge.

Sarah Bonazza1, Bruce Dalton2, Jori Hardin3, Andrei Metelitsa4.   

Abstract

Entities:  

Year:  2015        PMID: 26327709      PMCID: PMC4552236          DOI: 10.4212/cjhp.v68i4.1475

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


× No keyword cloud information.
  15 in total

1.  AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS.

Authors:  R D SWEET
Journal:  Br J Dermatol       Date:  1964 Aug-Sep       Impact factor: 9.302

2.  Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes.

Authors:  Luis Requena; Heinz Kutzner; Gabriele Palmedo; Marta Pascual; Jesús Fernández-Herrera; Javier Fraga; Amaro García-Díez; Evaristo Sánchez Yus
Journal:  Arch Dermatol       Date:  2005-07

3.  Drug-associated histiocytoid Sweet's syndrome: a true neutrophilic maturation arrest variant.

Authors:  Angela J Wu; Timothy Rodgers; Douglas R Fullen
Journal:  J Cutan Pathol       Date:  2008-02       Impact factor: 1.587

4.  Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.

Authors:  Cristina Alencar; Matthew Abramowtiz; Samir Parekh; Ira Braunshweig; Mark Jacobson; Lewis Silverman; Amit Verma
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

5.  Azacitidine: a new medication associated with Sweet syndrome.

Authors:  Suzanne Tintle; Vishal Patel; Andrea Ruskin; Charles Halasz
Journal:  J Am Acad Dermatol       Date:  2011-05       Impact factor: 11.527

6.  A case of Sweet's syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma.

Authors:  Angela Pang; Kong Bing Tan; Derrick Aw; Wen-Son Hsieh; Boon Cher Goh; Soo Chin Lee
Journal:  Cutan Ocul Toxicol       Date:  2011-08-26       Impact factor: 1.820

Review 7.  Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.

Authors:  D C Walker; P R Cohen
Journal:  J Am Acad Dermatol       Date:  1996-05       Impact factor: 11.527

8.  Azacitidine-associated Sweet's syndrome.

Authors:  Hannah B Trickett; Aaron Cumpston; Michael Craig
Journal:  Am J Health Syst Pharm       Date:  2012-05-15       Impact factor: 2.637

9.  Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

Authors:  Edvardas Kaminskas; Ann Farrell; Sophia Abraham; Amy Baird; Li-Shan Hsieh; Shwu-Luan Lee; John K Leighton; Hasmukh Patel; Atiqur Rahman; Rajeshwara Sridhara; Yong-Cheng Wang; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 10.  Drug-induced Sweet's syndrome.

Authors:  Dennis F Thompson; Kristin E Montarella
Journal:  Ann Pharmacother       Date:  2007-04-10       Impact factor: 3.154

View more
  5 in total

1.  A case of polycyclic Sweet's syndrome arising from azacitidine injection sites in myelodysplasia.

Authors:  William A Berry; Robert Kelly
Journal:  Ann Hematol       Date:  2019-12-09       Impact factor: 3.673

2.  Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome.

Authors:  Victoria Alegría-Landa; Socorro María Rodríguez-Pinilla; Angel Santos-Briz; José Luis Rodríguez-Peralto; Victor Alegre; Lorenzo Cerroni; Heinz Kutzner; Luis Requena
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

Review 3.  Sweet's syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine.

Authors:  George Yaghmour; Eric Wiedower; Bassam Yaghmour; Sara Nunnery; Eric Duncavage; Mike G Martin
Journal:  Ther Adv Hematol       Date:  2016-11-29

4.  A Sweet Diagnosis for a Non-Resolving Rash.

Authors:  Jian Liang Tan; Kah Poh Loh; Kshitij Thakur; Edward F Chan; Arezoo Ghaneie
Journal:  Cureus       Date:  2018-04-22

Review 5.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.